(Q43781170)

26 November 2017

title

Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. (English)

1 reference

26 November 2017

1 reference

Anne-Sophie Debrie

3

0 references

Nathalie Mielcarek

object named as

Nathalie Mielcarek

series ordinal

4

0 references

Camille Locht

object named as

Camille Locht

series ordinal

5

0 references

Hana Kammoun

series ordinal

2

object named as

Hana Kammoun

1 reference

26 November 2017

1

Pascal Feunou Feunou

1 reference

26 November 2017

language of work or name

English

0 references

publication date

13 August 2010

1 reference

26 November 2017

1 reference

26 November 2017

volume

28

1 reference

26 November 2017

issue

43

1 reference

26 November 2017

page(s)

7047-7053

1 reference

Pertussis of adults and infants

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

How best to estimate the global burden of pertussis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Stage II Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

Prevalence of markers of exposure to Bordetella pertussis among Italian young adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

Estimating the duration of pertussis immunity using epidemiological signatures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

Cell‐Mediated Immunity and Antibody Responses toBordetella pertussisAntigens in Children with a History of Pertussis Infection and in Recipients of an Acellular Pertussis Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

Duration of immunity against pertussis after natural infection or vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

Immunity to Bordetella pertussis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

Translating innate immunity into immunological memory: implications for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

A search for serologic correlates of immunity to Bordetella pertussis cough illnesses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

Protective activity of Bordetella adenylate cyclase-hemolysin against bacterial colonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

Heparin-inhibitable lectin activity of the filamentous hemagglutinin adhesin of Bordetella pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

inferred from DOI database lookup

7 January 2021

based on heuristic

Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.017

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.08.017

1 reference

26 November 2017

1 reference